Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP)

DEFENDANT NAME: Synergy Pharmaceuticals, Inc.
COURT: U.S. District Court for the Eastern District of New York
PRACTICE AREA: Investor Fraud
STATUS: Investigation
CLASS PERIOD: November 10, 2016 - November 14, 2017

Hagens Berman Sobol Shapiro LLP alertss investors in Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) to the expanded class period and the April 10, 2018 Lead Plaintiff Deadline in the pending securities class action in the U.S. District Court for the Eastern District of New York concerning loan disclosures.

If you purchased or otherwise acquired securities of SGYP between November 10, 2016 and November 14, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing

The complaint charges defendants with falsely describing the terms of a $300 million senior secured loan to Synergy as non-dilutive to shareholders.

However, when Synergy disclosed the loan agreement in an SEC filing on November 9, 2017, its terms revealed that the loan would likely be dilutive.  This news drove the price of Synergy shares down $0.25, or about 8.4%, to close at $2.72 on November 10, 2017.

Then, on November 14, 2017, Synergy filed a prospectus for the issuance of nearly 22 million shares and warrants to purchase nearly 22 million shares.  This news drove the price of Synergy shares down $0.14, or about 6.9% to close at $1.89 on November 15, 2017.

“We’re focused on the defendants’ statements about the financing’s impact on investors that, if false, damaged them,” said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding Synergy Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email

Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases


Please fill out the form below and we will get back to you as soon as we can.
File Upload *
Additional Information *
Send me: *

Case videos

Case Gallery

Case Timeline

02/13/18: Investigation